Clinical Trial Update: Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) [Phase 2]

View source ↗

Summary

Phase 2 trial update on thymoglobulin, sirolimus, and mycophenolate mofetil for preventing acute GVHD in hematologic malignancies; study terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies
• Leukemia
• Lymphoma
• Myelodysplastic Syndrome

Drugs mentioned

• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Sirolimus (Sirolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematological Malignancies, Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2014-02-20